On July 18, when CICI 2020 was held online, the “Cardiovascular OCT System” independently developed by the Vivolight team for 8 years was officially released to the world at the conference. As a high-performance domestic cardiovascular OCT system, it will break the long-term monopoly of such products by foreign products.
Leading figures in the cardiovascular field, Professor Ge Junbo, Academician of the Chinese Academy of Sciences, Professor Chen Yundai, Dean of the Graduate School of the Chinese People’s Liberation Army General Hospital and Director of the Department of Cardiovascular Medicine, Professor Zhou Yujie, Executive Vice President of Beijing Anzhen Hospital, Capital Medical University, Qian Juying, Zhongshan Hospital, Fudan University Dr. Zhu Rui, vice president and chairman of Vivolight, attended the press conference.
The imaging effect of the OCT system released by Vivolight is compared with the most advanced similar equipment in the world: the image is clearer, the outer diameter of the catheter is smaller and the distance between the catheter tip is shorter, and the passability and safety are better; it is unique in the world Features such as quantification of bifurcation lesions, automatic analysis of degradable stents, and one-click image sharing. The Chinese operation interface is simple and easy to use, following the seven-step OCT operation method, which conforms to the operation thinking of Chinese doctors. The intelligent software analysis system improves the efficiency of real-time image analysis and shortens the doctor’s learning curve and surgical analysis time.
Intracavitary imaging technology escorts PCI precision treatment, Vivolight OCT will greatly assist
In the opening speech at the launching conference of the OCT launch of Low Light, Professor Ge Junbo, a leading scholar in the field of cardiology in China and academician of the Chinese Academy of Sciences, pointed out that the number of PCI surgeries in China has increased sharply in the past 20 years, and it has exceeded one million in 2019. Precision treatment is imminent. Imaging technology can accurately evaluate PCI surgery and allow patients to receive the most effective treatment. In the past 16 years, Professor Chen Yundai has adhered to and advocated the concept of precision treatment. The CICI conference has become a vane of intracavitary imaging therapy and technical academic exchanges in China’s cardiovascular community. Dr. Zhu Rui is the first student of CCI. The R&D team he led has independently developed a high-quality cardiovascular OCT system, which will undoubtedly play a very important role in promoting the research and development of interventional cardiology in China.
High-level consultants and R&D team, quality is king, and “boutique”
Professor Chen Yundai, a leading scholar in the field of cardiology in China, Dean of the Graduate School of the People’s Liberation Army General Hospital and Director of the Department of Cardiovascular Medicine, shared with us the development history and clinical research data of the Vivolight cardiovascular OCT system, so that the majority of participants have a clear understanding of Vivolight cardiovascular How OCT, a “boutique”, was born.
Professor Yundai Chen shared the development history of Vivolight cardiovascular OCT
The low light cardiovascular OCT system is an incubation and key support project of Xi’an Institute of Optics and Mechanics, Chinese Academy of Sciences. Vivolight R&D leaders Dr. Zhu Rui, Dr. Li Jianan, and Dr. Cao Yihui are in the international leading position in the research and development of OCT system and intelligent analysis of medical images. Vivolight is China’s first national high-tech enterprise focusing on interventional intracavitary imaging. The team successfully developed the first cardiovascular 3D-OCT in 2013. After 7 years of engineering and clinical registration, it was launched in July 2020. Officially listed. During the period, a total of 49 invention patents were applied for and won the “Annual Original Technology Award” of the China Economic Forum.
Vivolight’s strong advisory team consists of Professor Chen Yundai, Dean of the Graduate School of the Chinese People’s Liberation Army General Hospital and Director of the Department of Cardiovascular Medicine, and Professor Dr. Gary Tearney of Harvard Medical School (the inventor of cardiovascular OCT, and still leads the world in the development of endoscopic OCT technology. ), Professor Dr. van Soest from the Medical Center of Erasmus University in Rotterdam, the Netherlands (a member of the International Working Group on OCT Standardization and Verification of Blood Vessels, currently leading the development and clinical research of multi-modal systems based on catheter imaging technology). Under the careful guidance of the consultant team, the Vivolight team adheres to the innovative concept of medical-industry integration, and takes the spirit of ingenuity as the standard, and strives for excellence in research and development and production of excellent performance-the Vivolight cardiovascular OCT system.
Professor Chen Yundai introduced: The “Vivolight Cardiovascular OCT System P60-Convenient Intelligent Platform” launched at the launch event. During the development process, R&D personnel continue to communicate with clinical experts to understand the surgeon’s operational thinking and habits, experience and surgical needs ; Innovatively developed OCT-Angio system, bifurcation lesion quantitative assessment system, biodegradable bio-stent automatic analysis function, one-key sharing and other more intelligent scientific research functions.
Vivolight OCT multiple intelligent scientific research functions
Director Chen Yundai pointed out: The Vivolight cardiovascular OCT system has a unique Pencil-beam technology, and the imaging depth is better than imported similar products. In terms of image depth and details, especially intelligent service software has certain advantages.
Seeing is better than hearing, the clinical verification results are gratifying
At the meeting, two experts from the Department of Cardiovascular Medicine of the Chinese People’s Liberation Army demonstrated the excellent imaging effects and innovative functions of Vivolight cardiovascular OCT with actual cases.
Director Jin Qinhua shared two cases of low-light OCT guidance for the treatment of bifurcation lesions and the placement of degradable stents at the meeting. Director Jin pointed out that the post-market research of the low-light OCT has been launched in the PLA General Hospital. The low-light OCT can calculate the branch opening area through 3D reconstruction to optimize the bifurcation treatment strategy, and the clear imaging can accurately guide the application of PSP technology in the process of degradable stent placement . In addition, Director Jin emphasized that Vivolight attaches great importance to the integration of medicine and industry, and that doctors’ ideas during use will be promptly fed back and optimized.
Low light OCT guides bifurcation lesions
Director Gao Lei shared the cases of in-stent restenosis with severe calcification lesions guided by low-light OCT at the meeting. In answering questions from the guests, Director Gao pointed out that OCT has more advantages than IVUS in the analysis of the thickness of calcified lesions and the properties of new plaques in the stent. The imaging catheter of low-light OCT is still very smooth in terms of passage.
Low-light OCT guides in-stent restenosis
Well-known domestic cardiovascular experts who came to the market meeting all gave high praise to Vivolight cardiovascular OCT.
Professor Zhou Yujie believes that the low-light OCT imaging catheter optical fiber probe is very stable, and there is no breakage of the optical fiber probe in various pathological applications in clinical trials. Although low-light OCT started late, it has a high starting point. Overcome, and the imaging quality is very good, the appearance of the equipment is high-end, atmospheric, and high-grade. It was once kept by the nurses of their hospital as imported equipment.
As Professor Zeng Hong of Jiangxi Provincial People’s Hospital who has personally experienced the VivolightOCT system, he was quite shocked by the low-light OCT resolution, excellent catheter passability and 3D analysis function. The bifurcation, angle measurement, and branch area measurement of the equipment’s scientific research analysis function cannot be measured on the latest imported OCT machine.
Professor Qian Juying used “to live up to expectations” to evaluate the results of VivolightOCT’s listing. She said that from the cases shared today, the image quality of Vivolight’s OCT system is not much different from imported products.
Professor Gao Chuanyu from the Fuwai Hua Hospital of Traditional Chinese Medicine commented that Vivolight was able to produce such a high-performance equipment in such a short period of time. The imaging effect is no different from that of imported products. This breakthrough is worth congratulating.
Professor Wang Liansheng from Jiangsu Provincial People’s Hospital also said that comparing Vivolight’s OCT system with similar competing products, the branch openings and apertures of Vivolight can be seen very clearly, and it is expected that it will benefit more patients in the future.
Guangqi future, low light plans to “intelligently” build multi-modal fusion intracavity imaging system
Zhu Rui, the founder of Vivolight, said: In the future, Vivolight will continue to deepen the R&D and innovation of interventional intracavitary imaging technology, thoroughly implement the innovative concept of medical-industry integration, refine its products, and actively promote the localization of high-end medical devices.
It is reported that Low Light is currently building a new generation of multi-modal fusion (four-in-one) intracavity imaging system, which will be easier to use and smarter, and is expected to be launched in 2021.
Multi-modal fusion (four in one) intracavity imaging system
The launch of VivolightOCT system equipment is a curve overtaking in the world’s high-end medical equipment field for China. It will popularize the application of OCT in the field of cardiovascular interventional therapy with more accurate image guidance, lower cost, and smarter surgical methods. , To provide cardiologists with a choice of tools, so that more coronary heart disease patients can get more accurate diagnosis and treatment.